EASTERN SHORE
CAPITAL MANAGEMENT
A Division of Moody Aldrich Partners

Small Cap Equity

First Quarter 2025

COMMENTARY

Eastern Shore exploits a market phenomenon known as the **Quality Anomaly** which refers to the consistent mispricing of quality companies that leads to their outperformance over time. The strategy focuses on higher quality stocks which tend to have lower volatility and lower risk of capital loss. The strategy also invests in companies experiencing positive change in quality drivers and prefers those with long runways for future growth. Valuation discipline is used to enhance returns.

Making Waves

Small Cap Equity Net Performance Statistics Since Inception (3/1/2007 – 3/31/2025)*

	Annualized Alpha (%)	Upside Capture (%)	Downside Capture (%)	Sharpe Ratio	Information Ratio
1 Year	2.0	88.6	88.5	-0.3	0.6
5 Year	-2.3	81.1	94.1	0.3	-0.7
10 Year	-0.2	86.3	92.0	0.2	-0.2
SI*	2.1	91.4	89.6	0.4	0.3

Note: *This information is presented as supplemental to the GIPS Report, which is available here. Statistics are calculated using net of fee performance. Net of fee performance was calculated by retroactively applying the highest model fee for the composite (.90%). Performance Statistics are calculated using the Russell 2000 index. The risk-free rate used to calculate the Sharpe ratio is the FTSE 3-month T-Bill. Contains performance from predecessor firm. See important notes at the end of this document. Inception date is 03/01/07. 2007's return represents a partial year beginning at the inception of the fund on 3/01/2007 and is not annualized. Performance from March 1, 2007 through October 26, 2012 occurred while Robert Barringer was the strategy's sole Portfolio Manager at FBR Asset Management.*

Markets/Economy

At the beginning of the new year, investors and businesses maintained optimism that the new administration would introduce a pro-growth agenda featuring an extension of the 2019 tax cuts and potentially enacting additional cuts as well. Anticipated decreases in regulations would make companies more efficient and spur M&A and IPOs. While the President was still vocal regarding tariffs, many investors assumed that new tariffs would serve as a negotiating tactic, much as they did during President Trump's first term. The nascent A.I. infrastructure buildout appeared to be a durable multi-year investment theme, enhancing the attractiveness of the opportunity set across a broad range of industries.

This relatively sanguine outlook persisted only until the end of January, when Chinese A.I. startup Deepseek announced that it had developed a low-cost A.I. model using a fraction of the computing power required by models developed by US firms. This news rattled technology stocks and brought into question how much capital would be needed to build out A.I. infrastructure here in the U.S. The assumption of U.S. dominance in the field of A.I. was also challenged given the non-U.S. firm's success in developing its model with a tiny fraction of the capital being invested by U.S. companies.

The next significant development emerged on February 1st, when the Trump Administration announced 25% tariffs on Canada & Mexico and an additional 10% on China. The President also mentioned that many product- and country-specific tariffs would be announced in the coming weeks. Market uncertainty rose as several soft economic data points deteriorated rapidly.

The March University of Michigan Consumer Sentiment Index of 57 reflected a significant decline from 74 last December. The NIFB Small Business Index dropped from 105.1 in February to 97.4 in March. The percentage of owners anticipating better business conditions dropped 16 points to a net 21%, marking the third consecutive monthly decline and the largest drop since December 2020. The Conference Board Consumer Confidence Index fell by 7.2 points in March to 92.9.

CONTINUED >>

The Conference Board's Expectations Index fell 9.6 points to 65.2, the lowest level in twelve years and well below the threshold of 80 – the level which usually precedes a recession. This soft data often precedes a deterioration in the hard economic data.

The increased volatility caused by these developments has created pockets of opportunity across our investment universe. While visibility is limited in the short term, we continue to seek out undervalued and mispriced stocks that can generate outsized long-term returns in this uncertain market.

Performance Summary *(through 03/31/2025)**

	1Q 2024	1 Year	3 Year (Annualized)	5 Year (Annualized)	10 Year (Annualized)	Since Inception 3/1/2007 (Annualized)
	(%)	(%)	(%)	(%)	(%)	(%)
Small Cap Equity (Gross)	-8.0	-0.8	0.8	10.4	6.5	9.2
Small Cap Equity (Net)	-8.2	-1.7	-0.1	9.4	5.5	8.2
Russell 2000	-9.5	-4.0	0.5	13.3	6.3	6.7
Strategy Excess Return (Gross)	1.5	3.2	0.3	-2.9	0.2	2.5
Strategy Excess Return (Net)	1.3	2.3	-0.6	-3.9	-0.8	1.5

This information is presented as supplemental to the GIPS Report, which is available **here. Statistics are calculated using net of fee performance. Net of fee performance was calculated by retroactively applying the highest model fee for the composite (.90%). Performance Statistics are calculated using the Russell 2000 index. The risk-free rate used to calculate the Sharpe ratio is the FTSE 3-month T-Bill. Contains performance from predecessor firm. See important notes at the end of this document. Inception date is 03/01/07. 2007's return represents a partial year beginning at the inception of the fund on 3/01/2007 and is not annualized. Performance from March 1, 2007 through October 26, 2012 occurred while Robert Barringer was the strategy's sole Portfolio Manager at FBR Asset Management.*

First Quarter 2025 Results

During the first quarter of 2025, the Eastern Shore Small Cap Equity Composite delivered a return of -8.00%/-8.21% gross and net of fees, outperforming the Russell 2000's -9.48% return for the quarter.

In a reversal from the previous quarter, the Russell 2000 Value index outperformed the Russell 2000 Growth by approximately 340 basis points. Higher quality companies – those with higher returns on equity (ROE) and returns on invested capital (ROIC) – significantly outperformed, as did stocks with lower betas. Higher market cap stocks outperformed as well, albeit by a smaller magnitude. These conditions provided a favorable environment for our quality-oriented approach, helping the strategy to outperform net of fees for a fifth consecutive quarter.

As is often the case, stock selection rather than sector allocation was the strongest influence on the strategy's relative performance for the quarter. The most significant positive sector contributors to the Small Cap Equity strategy's relative performance during the fourth quarter were Health Care and Financials. Biopharmaceutical holdings outperformed within Health Care, while outperformance in the Financials sector was driven by stock selection among non-bank financials, including both insurance and financial services firms.

Sector detractors for the quarter included Industrials and Real Estate. Within Industrials, the strategy's construction-related holdings detracted significantly from relative returns. The strategy lagged within the Real Estate sector largely because of the underperformance of its REIT holdings, though being underweight this outperforming sector weighed on relative performance as well. The team maintained its level of exposure to these two sectors during the quarter and made only three meaningful changes to sector allocation in this timeframe – increasing exposure to the Health Care sector by 4.3% and decreasing exposure to the Industrials and Consumer Discretionary sectors by 2.5% and 2.1%, respectively.

CONTINUED >>

No other sector adjustments exceeded 2% during the quarter. The decision to add exposure to Health Care was prompted by bottom-up stock selection among clinical-stage biopharmaceutical companies, while our reduction in exposure to Industrials and Consumer Discretionary holdings was driven by the decline in visibility caused by uncertainty regarding the new administration's tariff plans.

At the individual company level, the two most significant contributors to the strategy's performance for the quarter were biopharmaceutical firm Intra-Cellular Therapies (ITCI) and specialty insurance company Palomar Holdings (PLMR). Intra-Cellular Therapies announced in January that it was being acquired by Johnson & Johnson at a substantial premium, driving the stock's price up nearly 40%. Palomar's share price jumped in mid-February on a strong earnings report and continued to rise steadily through the rest of the quarter. Additional notable contributors during the quarter included residential loan provider Mr. Cooper Group (COOP) as well as biopharmaceutical holdings Halozyme Therapeutics (HALO) and Verona Pharma (VRNA). We sold Intra-cellular Therapies not long after the acquisition announcement, but we maintained exposure to the other four of these holdings as we felt that they offered additional upside.

The two most impactful detractors from the strategy's performance for the quarter were digital asset infrastructure firm Core Scientific (CORZ) and biopharmaceutical company Vaxcyte (PCVX). Core Scientific's share price declined in response to negative investor sentiment regarding data centers, while Vaxcyte's fell following its release of vaccine clinical trial data that fell short of expectations. Other significant detractors included biopharmaceutical firm Crinetics Pharmaceuticals (CRNX), semiconductor product manufacturer Semtech (SMTC), and construction services company Everus Construction Group (ECG). We sold Everus during the quarter due to uncertainty regarding the outlook for data center construction but maintained exposure to the other four holdings at quarter-end given their promising fundamentals.

From a positioning standpoint, we have maintained the balanced approach that has served the strategy well during the past two years: the strategy is not heavily biased towards growth or value, nor is it heavily concentrated or underweight in specific industries. We view the strategy as well-positioned to outperform in a volatile environment given its quality orientation and its exposure to company-specific catalysts that can offer additional upside.

Q1 2025 Top 5 Contributors†

Security	Ticker	Avg. Weight (%)
Intra-Cellular Therapies, Inc.	ITCI	0.5
Palomar Holdings, Inc.	PLMR	1.6
Mr. Cooper Group, Inc.	COOP	1.7
Halozyme Therapeutics, Inc.	HALO	1.2
Verona Pharma	VRNA	1.3

Q1 2025 Top 5 Detractors†

Security	Ticker	Avg. Weight (%)
Core Scientific, Inc.	CORZ	0.8
Vaxcyte, Inc.	PCVX	0.9
Crinetics Pharmaceuticals, Inc	CRNX	1.1
Semtech Corp.	SMTC	0.9
Everus Construction Group, Inc.	ECG	0.7

*†The information provided above should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this presentation or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and, in the aggregate, may represent only a small percentage of an account's portfolio holdings. It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein. A complete list of all securities recommended during the preceding year is available upon request. Past performance is not indicative of future results. The information is presented as supplemental to the GIPS Report available **here**. Top Contributors and Detractors are considered Extracted. Attribution total return for portfolio differs from composite results due to attribution methodology not taking intraday trading into account. Return data presented gross of fees. Past performance is not indicative of future returns.*

CONTINUED >>

Outlook

The degree of uncertainty regarding the global economy currently resembles that of March of 2020, when the world shut down in response to the pandemic. The path back to more normal market conditions then, as now, was impossible to predict. The difference today is that the tariffs put in place by the Trump administration can be reversed without notice.

At present, visibility into the path of inflation or economic growth is extremely limited. The dislocations in supply chains and the cost of ever-changing tariffs cannot be accurately estimated with the information currently available.

We will continue to look for and own high-quality businesses that have a reasonable path to visible growth in earnings and cash flow. Currently, we are emphasizing companies with greater domestic revenues and lower exposure to products and materials that are sourced in high tariff countries. Due to the uncertainty of the path of the economy, we also own many companies that have superior revenue visibility and are less economically sensitive. We continue to scrutinize economic data, and we are engaging in conversations with company management teams frequently to gain insight into the opportunities and challenges that this environment presents to their businesses. We will remain nimble and opportunistic as conditions change.

We appreciate your interest in Eastern Shore Capital Management – please feel free to reach out if you would like to discuss any of these issues in greater detail.

Robert Barringer, CFA
CIO, Partner, & Portfolio Manager

James O'Brien, CFA
Partner & Portfolio Manager

Sarah Westwood, CFA, CMT
Partner & Portfolio Manager

OFFICE CONTACT

18 Sewall Street
Marblehead, MA 01945

Phone
(781) 639-2750

Fax
(781) 639-2751

Disclosures

†The information provided in this report should not be considered a recommendation to purchase or sell any particular security. There is no assurance that any securities discussed herein will remain in an account's portfolio at the time you receive this report or that securities sold have not been repurchased. The securities discussed do not represent an account's entire portfolio and, in the aggregate, may represent only a small percentage of an account's portfolio holdings. It should not be assumed that any of the securities transactions or holdings discussed were or will prove to be profitable, or that the investment recommendations or decisions we make in the future will be profitable or will equal the investment performance of the securities discussed herein. A complete list of all securities recommended during the preceding year is available upon request. The information is presented as supplemental to the GIPS Report, which is available **here**.

The information contained in this document is subject to updating and verification and may be subject to amendment. No representation or warranty is expressed as to the accuracy of the information contained and no liability is given by Eastern Shore Capital Management as to the accuracy of the information contained in this document and no liability is accepted for any such information. This document and the information contained within it are confidential and intended solely for the use of the individual or entity to whom they are addressed. If you are not named addressee, you should not disseminate, distribute, or copy this document or any of the information contained within it.

Past performance is not necessarily indicative of future results. This document includes returns for the Russell 2000 index. The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. The Russell 2000 is a subset of the Russell 3000® Index representing approximately 10% of the total market capitalization of that index. It includes approximately 2000 of the smallest securities based on a combination of their market cap and current index membership. This index is not intended to be a direct benchmark for a particular strategy, nor is intended to be indicative of the type of assets in which a particular strategy may invest. The assets invested in on behalf of a client will likely be materially different from the assets underlying this index and will likely have a significantly different risk profile. Performance statistics, portfolio characteristics, portfolio holdings and other information included in this presentation are targets only and may change without notice to the client. The value of investments can go down as well as up. A client may not get back the amount invested.

Strategy Performance, Strategy Characteristics, Strategy Sector Weights, and Top Holdings, Strategy Statistics are reflecting the aggregate composite for the strategy. As such, individual accounts performance, weights, statistics, and characteristics may vary. †Inception date is 03/01/07. For the period of March 1, 2007 through October 26, 2012, the performance presented occurred while the Portfolio Manager was at a prior firm. Performance for this period has been calculated using custodial transactions for the fund while it was managed as a mutual fund (FBRYX) at FBR Asset Management. Eastern Shore Capital Management has met the requirements for claiming performance record portability and keeps the appropriate books and records as well as a portability memo on file. The Eastern Shore Capital Management Small Cap Equity Composite has undergone a portability examination for the period of March 1, 2007 through October 26, 2012. A client's return will be reduced by the advisory fees as described in Form ADV Part 2A and other expenses incurred by the account. For example, an annual advisory fee of .90% compounded quarterly over 3 years will reduce a gross 28.92% annual return to a net 28.1% annual return. Actual returns may vary from the performance information presented.

If you are not the named addressee you should not disseminate, distribute or copy this document or any of the information contained within it. If you are not the intended recipient you are notified that disclosing, copying, distributing or taking any action in reliance on the contents of this information is strictly prohibited.